“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

06 June 2019
Pharma

Visiongain has launched a new pharma report Global Precision Cancer Diagnostic Tests Market Forecasts 2019-2029: Lung Cancer, Breast Cancer, Colorectal Cancer, Blood Cancer, Gastric Cancer, HER-2 Positive, HR Positive, TNBC, Tissue Biopsy, Liquid Biopsy.

Over the past ten years, there has been a paradigm shift in the treatment of cancer, driven by advances in personalised medicine and immuno-oncology. The global precision cancer diagnostics tests market was estimated at $3.94 bn in 2018 and is expected to grow at a CAGR of 22.1% during the forecast period. The lung cancer submarket held 23% of the global precision cancer diagnostic tests market in 2018.

The lead analyst of the report commented "The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously. Thus, Visiongain believes that the focus on oncology and precision oncology diagnostics will remain high over the next decade driven by the ongoing research and development and growing number of partnerships between pharmaceutical and diagnostics players in this field.

Novel trends such as development of liquid biopsy-based tests will revolutionise the future of precision cancer diagnostic tests and as a result of this; the market will continue to achieve strong revenue growth."

Leading companies featured in the report include Abbott Laboratories, Agilent Technologies, Inc., bioMerieux SA, Genomic Health, Inc., Illumina, Inc., Myriad Genetics, Inc., Qiagen N.V., Roche Holding AG, Siemens Healthineers, Thermo Fisher Scientific, Inc. and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

Read

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

Read

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

Read

Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market

05 October 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever